2 years ago

CellCentric Secures £19.3 Million from Pfizer for Cancer Treatment

  • CellCentric, a Cambridge-based biotech company, has secured a £19.3 million investment from Pfizer to continue developing its cancer-treating drug, Inobrodib

  • The investment follows recent VC rounds from Morningside Venture Partners, 5Y Capital and BrightEdge, as well as grant funding from Innovate UK

  • CellCentric is developing a new method to treat patients with late-stage relapsed refractory multiple myeloma (RRMM).

      • ProblemHealthcare

      "treating patients with multiple myeloma who have relapsed to existing therapies"

      Solution

      "developing a new method called Inobrodib to target p300/CBP and potentially offer a new treatment option for these patients"

      Covered on